---
title: "RMH clonoSEQ(r) Assay"
ocid: "ocds-h6vhtk-05fb40"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-05fb40"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-05fb40.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-05fb40.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "THE ROYAL MARSDEN NHS FOUNDATION TRUST"
published: "2025-12-30"
---

# RMH clonoSEQ(r) Assay

Buyer: THE ROYAL MARSDEN NHS FOUNDATION TRUST  
Current stage: Award  
OCID: ocds-h6vhtk-05fb40

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-05fb40)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-05fb40.json)

## Summary

The Royal Marsden NHS Foundation Trust has concluded a procurement process for the "RMH clonoSEQ® Assay," focusing on the detection and monitoring of minimal residual disease (MRD) in haematologic malignancies. The procurement, facilitated via a direct award to Adaptive Biotechnologies Corporation, has been completed, with the contract scheduled to run from 20th January 2026 to 19th January 2031. The project addresses the medical industry category and takes place in London, UK, serviced under the central government's classification. The procurement process, driven by the unique capabilities and intellectual property owned by the supplier, was finalised on 22nd December 2025, with a total contract value of GBP 1,389,850. Key procurement stages include tender initiation and contract awarding.

This tender represents substantial opportunities for businesses involved in the provision of next-generation sequencing-based tests, software platforms, and associated technical support. Companies that specialise in laboratory reagents, particularly those with experience in complying with clinical guidelines and regulatory standards, are well-positioned to gain from similar contracts. The requirement for ongoing technical support, comprehensive delivery schedules, and integration with existing health systems opens avenues for both large-scale enterprises and SMEs focusing on healthcare diagnostics and biotechnologies. By engaging in such specialised contracts, businesses have the potential to enhance their market presence and contribute to advancements in medical diagnostics.

## Notice

The procurement of a next-generation sequencing (NGS)-based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL). The required goods and services include: * Provision of assay kits and reagents suitable for the intended patient population. * Use of a software platform for analysis and reporting of results. * Training and technical support for laboratory and clinical staff to ensure accurate sample processing, data interpretation, and integration into clinical workflows. * Ongoing technical support, maintenance, and updates for both hardware (if applicable) and software components. * Delivery of consumables and reagents on a schedule that aligns with clinical demand, ensuring continuity of patient testing. * Compliance with all relevant regulatory standards (e.g., CE-IVD, UKCA marking) and data protection requirements for patient information. * Optional: Integration with existing laboratory information management systems (LIMS) and electronic health records (EHR), if required. * MRD sensitivity threshold of 10-5 or lower * Must work on DNA * Performance data must be supported by evidence generated in relevant disease specific Clinical Trials * Recognised technology included in clinical guidelines * Ability to track clonal evolution

### Procurement Information

The supplier owns the IP for this assay. The unique factors are detailed below: Unique Capabilities: * Sensitivity: clonoSEQ can detect MRD down to one cancer cell among a million healthy cells, deeper than flow cytometry or PCR. This level of sensitivity is critical for accurately assessing MRD in patients for both depth of response and early relapse detection. * Standardization: clonoSEQ is a sole-source test. All reagents, materials, and equipment are needed to perform the assay. * FDA Approval: clonoSEQ is the first and only FDA-cleared assay for MRD detection ALL, CLL or MM. * Comprehensive Data Analysis: The assay includes sophisticated bioinformatics tools that offer detailed insights into clonal evolution and disease progression, which are not available with other MRD testing methods, resulting in a tracking report of disease burden over time. * Clinical Guidelines: NGS MRD assessment is included in clinical guidelines for ALL, CLL, DLBCL, and multiple myeloma. Monitoring MRD is crucial for assessing the treatment effectiveness and early detection of relapse in patients with lymphoid malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and multiple myeloma (MM). Traditional methods, such as flow cytometry and polymerase chain reaction (PCR), lack the sensitivity and standardisation required for consistent and deep MRD detection across different laboratories and clinical settings. The clonoSEQ Assay was developed by Adaptive Biotechnologies in accordance with CLIA/College of American Pathologists (CAP) requirements. Adaptive Biotechnologies is a single-source provider of the clonoSEQ Assay and therefore is uniquely positioned to meet the MRD detection needs for patients.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/086403-2025 |
| Notice type | UK6 - Contract Award Notice |
| Procurement type | Standard |
| Procurement category | Goods |
| Procurement method | Direct |
| Procurement method details | Direct award |
| Tender suitability | SME, VCSE |
| Awardee scale | SME |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 30 Dec 2025 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 22 Dec 2025 |
| Contract period | 20 Jan 2026 - 19 Jan 2031 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | £1,158,208 |
| Contracts value | Not specified |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Pending |
| Contracts status | Not specified |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE ROYAL MARSDEN NHS FOUNDATION TRUST |
| Additional buyers | CENTRAL LONDON COMMUNITY HEALTHCARE NHS TRUST |
| Locality | LONDON |
| Post town | South West London |
| Postcode | SW3 6JJ |
| Country | England |
| ITL 1 | TLI London |
| ITL 2 | TLI3 Inner London - West |
| ITL 3 | TLI35 Westminster and City of London |
| Local authority | Westminster |
| Electoral ward | Marylebone |
| Westminster constituency | Cities of London and Westminster |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | ADAPTIVE BIOTECHNOLOGIES |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33696500 - Laboratory reagents

## Release History

- 30 Dec 2025 at 11:11 - Award - UK6 - Contract Award Notice - https://www.find-tender.service.gov.uk/Notice/086403-2025
- 22 Dec 2025 at 10:38 - Award - UK5 - Transparency Notice - https://www.find-tender.service.gov.uk/Notice/085271-2025

## Documents

- https://www.find-tender.service.gov.uk/Notice/086403-2025
  30th December 2025 - Contract award notice on Find a Tender
- https://www.find-tender.service.gov.uk/Notice/085271-2025
  22nd December 2025 - Transparency notice on Find a Tender

## Notice URLs

- http://www.adaptivebiotech.com
- https://www.clch.nhs.uk
- https://www.legislation.gov.uk/ukpga/2023/54/contents
- https://www.royalmarsden.nhs.uk

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-05fb40. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-05fb40.json.